Longeveron Inc. (NASDAQ: LGVN) announced in July 2024 that the FDA granted Fast Track designation for its cellular therapy, Lomecel-B™, aimed at treating mild Alzheimer's Disease, accelerating its clinical development. The therapy also received RMAT designation, and the company announced a $9 million registered direct offering managed by H.C. Wainwright & Co.
Peraso Inc. (NASDAQ: PRSO) a leader in mmWave technology for 5G and 60 GHz networks, announced preliminary Q2 revenues of approximately $4.2 million, ending June 30, 2024, exceeding prior guidance. This represents a 50% sequential and 70% year-on-year growth. The stock has been trending upward, with investors anticipating it may rise above the 200 DMA and potentially challenge its three-month high of $2.04.
SiriusXM (NASDAQ: SIRI) reported year-on-year revenues at $2.16 billion, beating analysts' forecasts by 1.4%. The stock has surged from a multiyear low in the past month, likely due to a short squeeze ahead of its anticipated merger with Liberty Sirius XM Holdings, Read more.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) announced in July 2024, 3 new UK major manufacturers, have adopted its "Fingerprint Drug Screening System" for fast, reliable drug detection from fingertip sweat. Additionally, the system's successful biocompatibility testing advances it toward FDA 510(k) clearance, aiming for US market entry in 2025.
Catheter Precision (NYSE American: VTAK) implemented a new share structure on July 15, 2024, ensuring equal impact on shareholders. The company received evaluations and orders for its LockeT product from institutions such as UCLA Ronald Reagan Medical Center and HCA Healthcare. Their expansion strategy involves first introducing LockeT products to establish credibility, followed by the rollout of VIVO products. Additionally, the patient follow-up phase for the VIVO European Registry concluded in June 2023.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com
